MediWound Ltd. | Mutual Funds

Mutual Funds that own MediWound Ltd.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Hartford Healthcare Fund
1,020,809
3.76%
0
0.4%
07/31/2018
Hartford Healthcare HLS Fund
236,571
0.87%
0
0.43%
07/31/2018
Yelin Lapidot Menayatit
220,000
0.81%
0
0.36%
04/30/2018
USAA Science & Technology Fund
209,442
0.77%
0
0.09%
06/30/2018
203,797
0.75%
-74,850
0.28%
05/31/2018
U - Bank 20/80
165,000
0.61%
-60,000
2.7%
06/28/2018
Cavanal Hill Opportunistic Fund
141,823
0.52%
21,840
1.96%
06/30/2018
Yelin Lapidot Yeter
100,000
0.37%
0
0.59%
04/30/2018
Yelin Lapidot Gmisha Memukedet
100,000
0.37%
0
0.51%
06/28/2018
Modus Bonds 90/10
90,000
0.33%
0
2.85%
06/28/2018

About MediWound

View Profile
Address
42 Hayarkon Street
Yavne HM 8122745
Israel
Employees -
Website http://www.mediwound.com
Updated 07/08/2019
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialize novel products to address unmet needs in the fields of severe burn; chronic and other hard-to-heal wounds; and connective tissue disorders. Its medicinal product, NexoBrid, is used to remove eschar in adults patients with deep partial- and full-thickness thermal burns. The company was founded by Lior Rosenberg and Marian Gorecki on January 27, 2000 and is headquartered in Yavne, Israel.